Encysive Thelin pivotal trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Encysive plans to submit an NDA for Thelin (sitaxsentan) for pulmonary arterial hypertension "on or around the end of the first quarter in 2005." The company, formerly Texas Biotech, announced enrollment was complete for the Phase III Sitaxsentan To Relieve ImpaireD Exercise (STRIDE-2) study Sept. 8. The 240-patient, 18-week, double-blind, placebo-controlled trial includes a "third party bosentan [Actelion's Tracleer] arm," Encysive says. Topline data are expected in February 2005. The confirmatory trial is being conducted under FDA's special protocol assessment program (1Pharmaceutical Approvals Monthly Sept. 1, 2003, p. 17)...
You may also be interested in...
Encysive Thelin PAH submission
Encysive submits its oral endothelin receptor antagonist Thelin (sitaxsentan) for treatment of pulmonary arterial hypertension, the firm announces May 25. The NDA "contains the largest database ever assembled in a regulatory filing for PAH, with approximately 900 PAH patients receiving Thelin," the Houston-based company said. The NDA includes two pivotal trials, the second of which (STRIDE-2) was conducted under a special protocol assessment with FDA (1Pharmaceutical Approvals Monthly September 2004, In Brief). Thelin would be entering an increasingly competitive market: CoTherix' inhaled prostacyclin Ventavis (iloprost) cleared FDA last December (2Pharmaceutical Approvals Monthly January 2005, p. 3) and Pfizer's Revatio (sildenafil) cleared FDA June 3 (see related brief, p. 15)...
Special Protocol Assessment Requests Up 10%-15% Over FY2002
Sponsor requests for special protocol assessments continue to rise with a 10% to 15% increase so far in 2003, according to FDA.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.